Kaleido Biosciences, Inc.
KLDOOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$4262
P/E Ratio—
52W High$0.19
52W Low$0.00001
Kaleido Biosciences, Inc. (KLDO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KLDO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2022Report Date: Apr 1, 2022EPS Actual
-$0.47
Est. -$0.58 · +19.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2022
FY ends December
Report Date
Apr 1, 2022
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
KLDO reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.58 | — | — | — | $0.00B | — |
| ◌ Q2 FY2026 | May 29, 2026 | — | — | — | — | — | — |
| ◌ Q2 FY2026 | May 5, 2026 | -$0.58 | — | — | — | $0.00B | — |
| ◌ Q1 FY2026 | Mar 4, 2026 | -$0.59 | — | — | — | $0.01B | — |
| ◌ Q2 FY2023 | May 22, 2023 | — | — | — | — | — | — |
| ◌ Q1 FY2023 | Mar 27, 2023 | -$0.51 | — | — | — | — | — |
| ◌ Q4 FY2022 | Dec 19, 2022 | — | — | — | — | — | — |
| ▲ Q2 FY2022 | Apr 1, 2022 | -$0.58 | -$0.47 | +19.0% | — | $0.00B | — |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.58
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 29, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026
EPS Actual
—
EPS Est.
-$0.58
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 4, 2026
EPS Actual
—
EPS Est.
-$0.59
EPS Surpr.
—
Revenue
—
Q2 FY2023
May 22, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 27, 2023
EPS Actual
—
EPS Est.
-$0.51
EPS Surpr.
—
Revenue
—
Q4 FY2022
Dec 19, 2022
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2022
Apr 1, 2022Beat
EPS Actual
-$0.47
EPS Est.
-$0.58
EPS Surpr.
+19.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q2 FY2029 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q1 FY2029 | $-0.22 | $-0.22 | $-0.22 | 1 |
| Q4 FY2028 | $-0.17 | $-0.17 | $-0.17 | 1 |
| Q3 FY2028 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q2 FY2028 | $-0.22 | $-0.22 | $-0.22 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2022 | Apr 1, 2022 | +19.0% | $1.65 | $1.70 | +3.03% |
| — Q4 FY2021 | Dec 31, 2021 | — | $2.65 | $2.39 | -9.81% |
| ▲ Q4 FY2021 | Nov 1, 2021 | +0.0% | $4.30 | $4.47 | +3.95% |
| ▲ Q3 FY2021 | Aug 11, 2021 | +1.8% | $6.00 | $6.23 | +3.83% |
| ▲ Q2 FY2021 | May 4, 2021 | +1.7% | $7.36 | $7.11 | -3.40% |
Q2 FY2022+3.03%
Report Date
Apr 1, 2022
EPS Beat/Miss
+19.0%
Price Before
$1.65
Price After
$1.70
Q4 FY2021-9.81%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$2.65
Price After
$2.39
Q4 FY2021+3.95%
Report Date
Nov 1, 2021
EPS Beat/Miss
+0.0%
Price Before
$4.30
Price After
$4.47
Q3 FY2021+3.83%
Report Date
Aug 11, 2021
EPS Beat/Miss
+1.8%
Price Before
$6.00
Price After
$6.23
Q2 FY2021-3.40%
Report Date
May 4, 2021
EPS Beat/Miss
+1.7%
Price Before
$7.36
Price After
$7.11
Avg Beat Reaction+1.85%
Beat Rate4 / 5 quarters
Largest Move-9.81% (Q4 FY2021)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KLDO ends December
Kaleido Biosciences, Inc. (KLDO) most recently reported earnings on April 1, 2022 for Q2 FY2022, posting EPS of $-0.47 — beating the analyst consensus of $-0.58 by +19.0%. KLDO has beaten EPS estimates for 4 consecutive quarters. The next KLDO earnings date is expected around September 1, 2026.
Each quarter, investors track KLDO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KLDO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KLDO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KLDO earnings · 5 questionsKaleido Biosciences, Inc.'s next earnings report is expected around September 1, 2026. KLDO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KLDO historically reports after market close (AMC).
KLDO earnings datewhen is KLDO earningsKLDO next earnings datewhen does KLDO report earningsKLDO earnings calendar
▸ Source: FMP · Kaleido Biosciences, Inc. SEC filings · US GAAP · Kaleido Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026